诺诚健华早盘涨超7% 坦昔妥单抗全国多省市首批处方落地

新浪港股
Yesterday
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  诺诚健华(09969)早盘股价上涨7.18%,现报18.97港元,成交额1.35亿港元。

  据诺诚健华官微消息,近日,公司宣布,靶向CD19单抗明诺凯®(坦昔妥单抗,tafasitamab)近日在北京、上海、广东、黑龙江、福建、山东、广西、安徽、江西、湖北、浙江等全国多个省市医院开出首批处方,标志着这款创新药在中国正式进入临床应用阶段。据介绍,坦昔妥单抗是全球首个且唯一获批治疗淋巴瘤的CD19单抗,也是中国首个获批治疗复发/难治性弥漫性大B细胞淋巴瘤(R/R DLBCL)的CD19单抗,填补了国内CD19靶向治疗的空白,将为DLBCL患者带来更好的治疗选择。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10